• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024

    9/9/24 4:00:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSBR alert in real time by email

    HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 726315. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51258, or by accessing the investors section of the company's website within 72 hours.

    About Champions Oncology, Inc.
    Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

    Media Contact:
    Rachel Bunting, MS, MBA
    VP, Global Marketing
    [email protected]

    SOURCE: Champions Oncology, Inc.



    View the original press release on accesswire.com

    Get the next $CSBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSBR

    DatePrice TargetRatingAnalyst
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $CSBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces the Addition of Brady Davis as President

      HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth."We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.Mr. Davis brings more than 25 years of international experience leading medical

      10/17/23 8:30:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces Addition to Board of Directors

      HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff. Joel Ackerman, Chairman of the Board of Directors commented

      2/22/21 9:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Financials

    Live finance-specific insights

    See more
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

      HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided

      9/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Breitfeld Philip P. disposed of 4,150 shares, decreasing direct ownership by 42% to 5,717 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      4/2/25 4:20:36 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Breitfeld Philip P.

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 12:14:09 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sidransky David

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 11:47:41 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/16/24 11:45:44 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/12/24 12:47:07 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/11/24 10:57:35 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    SEC Filings

    See more

    $CSBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CSBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CSBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/17/25 11:03:52 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/11/25 4:32:41 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      12/16/24 4:16:03 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Champions Oncology from Hold to Buy and set a new price target of $6.00

      9/12/24 9:23:16 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roth Capital reiterated coverage on Champions Oncology with a new price target

      Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously

      3/15/21 10:03:32 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

      SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      11/14/24 9:53:10 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)

      SC 13D/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      5/6/24 7:46:06 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Champions Oncology Inc.

      SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      2/12/24 9:12:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care